AZD1480

For research use only. Not for use in humans.

目录号：S2162

CAS No. 935666-88-9

AZD1480是一种新型，ATP竞争性的JAK2抑制剂，无细胞试验中IC50为0.26 nM，选择性作用于JAK3和Tyk2，对JAK1的作用较弱。Phase 1。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1071.19	现货
5mg	RMB 819.48	现货
50mg	RMB 4671.71	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的AZD1480发表文献87篇：

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 175(2):458-471

PubMed: 30173917 ( click the link to review the publication )

Cancer Cell, 2018, 34(2):315-330

PubMed: 30033091 ( click the link to review the publication )

Cell Metab, 2017, 25(6):1320-1333

PubMed: 28591635 ( click the link to review the publication )

Nat Med, 2015, 21(1):47-54

PubMed: 25485912 ( click the link to review the publication )

Blood Cancer J, 2021, 11(6):111

PubMed: 34099621 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1205

PubMed: 33801977 ( click the link to review the publication )

Cancers (Basel), 2021, 13(7)1579

PubMed: 33808059 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2021, 2021:5591687

PubMed: 34211571 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(26):15047-15054

PubMed: 32532922 ( click the link to review the publication )

PLoS Biol, 2020, 18(3):e3000646

PubMed: 32203518 ( click the link to review the publication )

Clin Cancer Res, 2020,

PubMed: 32887724 ( click the link to review the publication )

Front Immunol, 2020, 14;11:867

PubMed: 32477351 ( click the link to review the publication )

Carcinogenesis, 2020, 41(7):993-1004

PubMed: 31740922 ( click the link to review the publication )

Oncogenesis, 2020, 10;9(2):15

PubMed: 32041943 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.0186.2020

PubMed: 33004621 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(1):e000285

PubMed: 32581055 ( click the link to review the publication )

Eur Arch Otorhinolaryngol, 2020, 10.1007/s00405-020-06274-3

PubMed: 32783069 ( click the link to review the publication )

Nat Commun, 2019, 10(1):716

PubMed: 30755611 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3601

PubMed: 31399589 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2808

PubMed: 31806641 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 18;38(1):85

PubMed: 30777101 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30634502 ( click the link to review the publication )
Cancers (Basel), 2019, 11(9)

PubMed: 31540495 ( click the link to review the publication )

Cell Death Discov, 2019, 5:72

PubMed: 30854231 ( click the link to review the publication )

Cancer Discov, 2019,

PubMed: 30366930 ( click the link to review the publication )

Front Immunol, 2019, 1.1243055556

PubMed: 31156620 ( click the link to review the publication )

Gastric Cancer, 2019, 22(3):486-496

PubMed: 30264329 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):384

PubMed: 31842997 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(6):4301-4312

PubMed: 30993883 ( click the link to review the publication )

Lab Invest, 2019, 99(12):1810-1821

PubMed: 31467427 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2019, 316(3):L487-L497

PubMed: 30604628 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0254-4

PubMed: 31201357 ( click the link to review the publication )

J Microbiol Biotechnol, 2019, 29(12):2006-2013

PubMed: 31581384 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(10):1689-1704

PubMed: 31314158 ( click the link to review the publication )

Reproduction, 2019, 158(4):303-312

PubMed: 31408846 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 30401677 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4345

PubMed: 30341316 ( click the link to review the publication )

Cancer Lett, 2018, 429:54-65

PubMed: 29729901 ( click the link to review the publication )

Metabolism, 2018, 79:10-23

PubMed: 29080813 ( click the link to review the publication )

Int J Obes , 2018, 42(2):252-259

PubMed: 28925407 ( click the link to review the publication )

J Cell Sci, 2018, 131(10)

PubMed: 29678906 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 314(5):L882-L892

PubMed: 29345196 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2018, 9:424

PubMed: 30140255 ( click the link to review the publication )

Int J Oncol, 2018,

PubMed: 30015925 ( click the link to review the publication )

Mol Immunol, 2018, 101:221-228

PubMed: 30007232 ( click the link to review the publication )

Molecules, 2018, 23(6)E1478

PubMed: 29921758 ( click the link to review the publication )
Blood, 2017, 129(14):1969-1979

PubMed: 28151428 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(11):2934-2939

PubMed: 28246332 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):1643-1648

PubMed: 28130546 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

Oxid Med Cell Longev, 2017, 2017:7601592

PubMed: 29147463 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(7):852-861

PubMed: 28314843 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 29259270 ( click the link to review the publication )

Endocrinology, 2017, 158(7):2255-2268

PubMed: 28444169 ( click the link to review the publication )

Oncotarget, 2017, 8(53):91516-91529

PubMed: 29207662 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109319-109331

PubMed: 29312610 ( click the link to review the publication )

J Clin Invest, 2016, 126(4):1300-10

PubMed: 26927669 ( click the link to review the publication )

Nat Commun, 2016, 7:12428

PubMed: 27687249 ( click the link to review the publication )

Small, 2016, 12(24):3270-82

PubMed: 27167493 ( click the link to review the publication )

Neuro Oncol, 2016, 10.1093/neuonc/now139

PubMed: 27402815 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(11):2758-2765

PubMed: 27566291 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2016, 14:119-27

PubMed: 26607555 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(1):9-23

PubMed: 26494904 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):57-67

PubMed: 25487280 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Sci Rep, 2015, 5:13414

PubMed: 26299368 ( click the link to review the publication )

Mol Pharmacol, 2015, 87(4):572-81

PubMed: 25583084 ( click the link to review the publication )

Mol Pharmacol, 2015, 87(4):572-81

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 458(4):908-12

PubMed: 25704089 ( click the link to review the publication )
Biochem Biophys Res Commun, 2015, 458(4):908-12

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 8(48):83457-83468

PubMed: 29137356 ( click the link to review the publication )

Oncotarget, 2015, 6(29):28401-24

PubMed: 26315114 ( click the link to review the publication )

Blood, 2014, 123(10):1516-24

PubMed: 24408322 ( click the link to review the publication )

Autophagy, 2014, 10(7):1212-28

PubMed: 24813621 ( click the link to review the publication )

J Med Chem, 2014, 57(15):6342-53

PubMed: 24978112 ( click the link to review the publication )

Oncol Rep, 2014, 32(5):1991-8

PubMed: 25216185 ( click the link to review the publication )

PLoS One, 2014, 9(10):e109799

PubMed: 25289677 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112014

PubMed: 25390891 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(42):16975-80

PubMed: 24082147 ( click the link to review the publication )

Cancer Lett, 2013, 341(2):224-30

PubMed: 23941832 ( click the link to review the publication )

Endocrinology, 2013, 154(9):3219-27

PubMed: 23782942 ( click the link to review the publication )

Asian Pac J Cancer Prev, 2013, 14(8):4823-7

PubMed: 24083752 ( click the link to review the publication )

Leukemia, 2012, 26(4):708-15

PubMed: 21926964 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(6):M112.017764

PubMed: 22345495 ( click the link to review the publication )

产品安全说明书

JAK抑制剂选择性比较

生物活性

产品描述

AZD1480是一种新型，ATP竞争性的JAK2抑制剂，无细胞试验中IC50为0.26 nM，选择性作用于JAK3和Tyk2，对JAK1的作用较弱。Phase 1。

特性

AZD1480为治疗多发性骨髓瘤的潜在新型治疗剂。

靶点

JAK2 ^[1]
(Cell-free assay)

0.26 nM

体外研究

5μM AZD1480诱导细胞周期停在G2/M期，且通过抑制Aurora激酶而诱导细胞死亡。^[1]AZD1480是JAK2的有效抑制剂，作用于人类多发性骨髓瘤细胞，可以抑制生长，存活，FGFR3 和 STAT3信号，及下游靶点，包括 Cyclin D2。在低微摩尔浓度时，AZD1480抑制细胞增殖和诱导骨髓瘤细胞系凋亡。^[2]AZD1480 作用于人和鼠神经胶质瘤细胞，有效抑制组成型和诱导型JAK1, JAK2, 及STAT-3的磷酸化作用，结果导致细胞增殖降低，且诱导凋亡。^[3]AZD1480是有效的ATP竞争性的JAK1/2激酶小分子抑制剂，可抑制STAT3磷酸化和肿瘤生长，这种抑制存在STAT3依赖性。AZD1480通过影响肿瘤的微环境而抑制肿瘤血管生成和局部转移。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
SW620	MkjNSpVv[3Srb36gRZN{[Xl?	MUS1JO69VQ>?	NV;wdldyPDhiaB?=	M4TocmROW09?	NW\wUYtz[myxY3vzJGpCUzJxU2TBWFMhe2mpbnHsbY5o	Mo\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NUS5O\|QoRjJ3OUW0PVc1RC:jPh?=
LoVo	MV3GeY5kfGmxbjDBd5NigQ>?	NHjTXo02KM7:TR?=	MUW0PEBp	MWLEUXNQ	NFrUe5NjdG:la4OgTmFMOi:VVFHUN{B{cWewYXzpcoc>	NF7jWXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm1OFk4PCd-MkW5OVQ6PzR:L3G+
HN5	M3\SVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHzTfHc4OiCq		M3jGdWVEPTB;Mz64NUDDuSBzLkm5JO69VQ>?	Mn;EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCwNVAoRjJ3OEGwNFExRC:jPh?=
Cal33	NIPvfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYe3NkBp		NFLDUXpGSzVyPUOuN\|chyrFiMD63OUDPxE1?	M4Pkc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEGwNFExLz5{NUixNFAyODxxYU6=
UM-22B	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXT1c\|REPzJiaB?=		NEnBR4dGSzVyPUKuOlYhyrFiMD6yOEDPxE1?	MmDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCwNVAoRjJ3OEGwNFExRC:jPh?=
686LN	NUPiXopKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH7vRlI4OiCq		MXnFR\|UxRTJwMEWgxtEhOS5\|MzFOwG0>	M2nrZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEGwNFExLz5{NUixNFAyODxxYU6=
UM SCC-1	MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M33yWFczKGh?		Ml;3SWM2OD1zLk[3JOKyKDBwNEKg{txO	NEfvOmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixNFAyOCd-MkW4NVAxOTB:L3G+
UM-22A	Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{LiTlczKGh?		MUfFR\|UxRTFwM{KgxtEhOC5\|OTFOwG0>	NGrDZnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixNFAyOCd-MkW4NVAxOTB:L3G+
OSC19	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYO3NkBp		NXPrTG5pTUN3ME2xMlI3KMLzIECuNlAh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMECxNEc,OjV6MUCwNVA9N2F-
PCI-52	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUi3NkBp		NGDHNoFGSzVyPUGuNFAhyrFiMD6wPUDPxE1?	NEHNfIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixNFAyOCd-MkW4NVAxOTB:L3G+
PCI-15B	NX3QVXV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX;wVIpzPzJiaB?=		Mn\1SWM2OD1yLkm5JOKyKDFwN{Sg{txO	NHTWSlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixNFAyOCd-MkW4NVAxOTB:L3G+
UMSCC-1	NXi1d3h3TnWwY4Tpc44hSXO\|YYm=	NXfZS2dbOC5yMEC1MVEvPiEQvF2=	M2HYW\|I1KGh?		Mmn4ZYJzd2ejdHXzJGlNNTckgKPpcoR2[2WmIIXwMZJm\3WuYYTpc44hd2ZicGPURXQ{XHm{N{C1xsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M2jiOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEGwNFExLz5{NUixNFAyODxxYU6=
Cal33	NF\xblFHfW6ldHnvckBCe3OjeR?=	NYftWZRwOC5yMEC1MVMvQCEQvF2=	NYLLb\|BtOjRiaB?=		NYDZWXI6[WK{b3fheIV{KEmOLUdihLNqdmS3Y3XkJJVxNXKnZ4XsZZRqd25ib3[gdHNVSVR\|VInyO\|A2yqCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M3TFWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEGwNFExLz5{NUixNFAyODxxYU6=
HH5	MoXiSpVv[3Srb36gRZN{[Xl?	MXqwMlAxODVvMz64JO69VQ>?	MVSyOEBp		NIHjRoJi[nKxZ3H0[ZMhUUxvNvMAl4lv\HWlZXSgeZAuemWpdXzheIlwdiCxZjDwV3RCXDOWeYK3NFXDqGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMECxNEc,OjV6MUCwNVA9N2F-
UM-22A	MVjGeY5kfGmxbjDBd5NigQ>?	M1O2O\|AvODByNT2xMlYh\|ryP	NIDRUZQzPCCq		MoK1ZYJzd2ejdHXzJGlNNTckgKPpcoR2[2WmIIXwMZJm\3WuYYTpc44hd2ZicGPURXQ{XHm{N{C1xsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MkPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCwNVAoRjJ3OEGwNFExRC:jPh?=
A1847	MV3GeY5kfGmxbjDBd5NigQ>?	MWewMlA2NTFyIN88US=>	MYiyOEBp	NFHoPJJFVVORwrC=	NEH6RYpz\WS3Y3XzJJBpd3OyaH;yfYxifGWmIGPURXQ{KGyndnXsdy=>	M3nIXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkS2NFE2Lz5{NU[0OlAyPTxxYU6=
OVCAR-5	NXXxT2ptTnWwY4Tpc44hSXO\|YYm=	MVGwMlA2NTFyIN88US=>	M2DoXFI1KGh?	MVrEUXNQyqB?	MoeydoVlfWOnczDwbI9{eGixconsZZRm\CCVVFHUN{Bt\X[nbIO=	Mn72QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NE[wNVUoRjJ3NkS2NFE2RC:jPh?=
OVCAR-8	NGPtW5pHfW6ldHnvckBCe3OjeR?=	NFzwbFUxNjB3LUGwJO69VQ>?	MmTENlQhcA>?	MmjWSG1UV8Li	M2rpOpJm\HWlZYOgdIhwe3Cqb4L5cIF1\WRiU2TBWFMhdGW4ZXzz	NV7hfYlsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OFYxOTVpPkK1OlQ3ODF3PD;hQi=>
MOVCAR-5447	NGDHS4ZHfW6ldHnvckBCe3OjeR?=	MnPwNE4xPS1zMDFOwG0>	MlfsNlQhcA>?	MlXMSG1UV8Li	NYLMOWN4emWmdXPld{BxcG:\|cHjvdplt[XSnZDDTWGFVOyCuZY\lcJM>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ2NkCxOUc,OjV4NE[wNVU9N2F-
MOVCAR-5009	MkLkSpVv[3Srb36gRZN{[Xl?	NIX1PZYxNjB3LUGwJO69VQ>?	M4iyXlI1KGh?	MYfEUXNQyqB?	MmKydoVlfWOnczDwbI9{eGixconsZZRm\CCVVFHUN{Bt\X[nbIO=	Mni4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NE[wNVUoRjJ3NkS2NFE2RC:jPh?=
A1847	M363TGNmdGxiVnnhZoltcXS7IFHzd4F6	NYLNPVk5OC5yNT2xNEDPxE1?	M3ThOlczKGh?	NEjmTGFFVVOR	MoL3doVlfWOnczDj[YxtKH[rYXLpcIl1gSCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhPSEQvF2=	NGrVRnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[0OlAyPSd-MkW2OFYxOTV:L3G+
OVCAR-5	M3vQ[mNmdGxiVnnhZoltcXS7IFHzd4F6	NUHsOVNJOC5yNT2xNEDPxE1?	MYS3NkBp	MUPEUXNQ	NHHWUW9z\WS3Y3XzJINmdGxidnnhZoltcXS7IHH0JJRp\SClb37j[ZJvfHKjdHnvckBw\iB3IN88US=>	NI\ne2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[0OlAyPSd-MkW2OFYxOTV:L3G+
OVCAR-8	MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MWiwMlA2NTFyIN88US=>	NYXTe4xkPzJiaB?=	MXnEUXNQ	MnTydoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhPSEQvF2=	MoL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NE[wNVUoRjJ3NkS2NFE2RC:jPh?=
OVCAR-5	NYiyPGxQSXCxcITvd4l{KEG\|c3H5	NGLOPXIxNjVxMT:1JO69VQ>?	NGTVXWw1QCCq	NXzrcVVVTE2VTx?=	NFy4UGRqdmS3Y3XzJJNq\26rZnnjZY51KGGyb4D0c5NqeyCjdDDobYdpKGOxbnPldo51emG2aX;u	M4rxfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkS2NFE2Lz5{NU[0OlAyPTxxYU6=
OVCAR-8	M2j4eWFxd3C2b4Ppd{BCe3OjeR?=	M3jVfVAvPS9zL{Wg{txO	M{fMPFQ5KGh?	M4PaOmROW09?	NWW5bnBRcW6mdXPld{B{cWewaX\pZ4FvfCCjcH;weI9{cXNiYYSgbIlocCClb37j[ZJvfHKjdHnvci=>	MnfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NE[wNVUoRjJ3NkS2NFE2RC:jPh?=
AKRSL	MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>		MoLqO\|IhcA>?		M3;IOGlEPTExvK6xNEDPxE1?	M2fwdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUC0OlM2Lz5{NUWwOFY{PTxxYU6=
PALJDL	NVLGXGxpS2WubDDWbYFjcWyrdImgRZN{[Xl?		MlLnO\|IhcA>?		M37USGlEPTB;Mj60JO69VQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTVyNE[zOUc,OjV3MES2N\|U9N2F-
MO4	M4TWdGZ2dmO2aX;uJGF{e2G7	NVLlR3JzOC53L{GvOUDPxE1?	M{L5[\|YhcA>?		Ml7VbY5pcWKrdIOgVE1UXEGWMzDlfJBz\XO\|aX;uxsA>	NEX6V5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0PVU{PSd-MkWxOFk2OzV:L3G+
DU145	M4LLbGZ2dmO2aX;uJGF{e2G7	MV[wMVIxOCCwTR?=	NUi2bJRCOSCqwrC=		NHvDdXl{fXCycnXzd4V{KEmOLU[tZYN1cX[jdHXkJHN1[XR\|IHHu[EBGWktzL{Kgd4lodmGuaX7n	MmL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3N{e5OFIoRjJ2NUe3PVQzRC:jPh?=
DU145	NWXncph1TnWwY4Tpc44hSXO\|YYm=	Mn3FPFAxKG6P	M1u3clczKGh?		Mn;Xd5VxeHKnc4Pld{BKVC14LXnu[JVk\WRibXnndoF1d3K7	M4PhNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUe3PVQzLz5{NEW3O\|k1OjxxYU6=
CWR22Rv1	NImzS2NHfW6ldHnvckBCe3OjeR?=	MojGPFAxKG6P	MlPRO\|IhcA>?		NYDBclhbe3WycILld5NmeyCLTD22MYlv\HWlZXSgcYloemG2b4L5	MnHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3N{e5OFIoRjJ2NUe3PVQzRC:jPh?=
N592	Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvzTWM2OD1yLki0JO69VQ>?	MmD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUi3NFEoRjJ2MUW4O\|AyRC:jPh?=
H82	MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvVTWM2OD1zLkO3JO69VQ>?	MnTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUi3NFEoRjJ2MUW4O\|AyRC:jPh?=
GLC4	M2Hxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvLNXBQUUN3ME2xMlc6KM7:TR?=	NIjVZWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1PFcxOSd-MkSxOVg4ODF:L3G+
H526	NWS4[ZNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{j1Z2lEPTB;Mz6wPEDPxE1?	M1f4VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUW4O\|AyLz5{NEG1PFcxOTxxYU6=
H1173	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnO2TWM2OD1{LkO5JO69VQ>?	M1j6TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUW4O\|AyLz5{NEG1PFcxOTxxYU6=
DMS114	NILFWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\Oc4lpUUN3ME2wMlc{KM7:TR?=	Mkm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUi3NFEoRjJ2MUW4O\|AyRC:jPh?=
NCI-N592	NIq2NWdHfW6ldHnvckBCe3OjeR?=	MYCwMlMwOS9\|IN88US=>	MV[yOEBp		M2P5SYlv\HWlZYOgS\|IwVSClZXzsJIN6[2ynIHHydoV{fA>?	NEO5WZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1PFcxOSd-MkSxOVg4ODF:L3G+
GLC4	NFLafZlHfW6ldHnvckBCe3OjeR?=	MUewMlMwOS9\|IN88US=>	NIezTGUzPCCq		NVv5OHRWcW6mdXPld{BIOi:PIHPlcIwh[3mlbHWgZZJz\XO2	NU\aToN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVg4ODFpPkK0NVU5PzBzPD;hQi=>
NCI-H82	M4iwXmZ2dmO2aX;uJGF{e2G7	M3rIW\|AvOy9zL{Og{txO	MV2yOEBp		Ml\SbY5lfWOnczDHNk9OKGOnbHygZ5lkdGViYYLy[ZN1	Mnz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUi3NFEoRjJ2MUW4O\|AyRC:jPh?=
NCI-N592	NFHBfWZCeG:ydH;zbZMhSXO\|YYm=	MkPGNE4{NzFxMzFOwG0>	MYm0PEBp		NEHZWnNqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIHPs[YF3\WRvQ3HzdIF{\SB\|	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF3OEewNUc,OjRzNUi3NFE9N2F-
GLC4	NEXOOnhCeG:ydH;zbZMhSXO\|YYm=	MXKwMlMwOS9\|IN88US=>	NGXiPGY1QCCq		MkXLbY5kemWjc3XzJJRp\SCuZY\lcEBw\iClbHXheoVlNUOjc4Dhd4UhOw>?	MlXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUi3NFEoRjJ2MUW4O\|AyRC:jPh?=
NCI-H82	NFzGNIFCeG:ydH;zbZMhSXO\|YYm=	MV[wMlMwOS9\|IN88US=>	NUXKcVlJPDhiaB?=		MWjpcoNz\WG\|ZYOgeIhmKGyndnXsJI9nKGOuZXH2[YQuS2G\|cHHz[UA{	M2LuRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUW4O\|AyLz5{NEG1PFcxOTxxYU6=
CWR22Rv1	NYrRdHptSXCxcITvd4l{KEG\|c3H5				MWHJR\|UxRTBwNEiyJO69VQ>?	M3r3eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUSyNFk2Lz5{M{m0NlA6PTxxYU6=
CWR22Pc	M2TEWmFxd3C2b4Ppd{BCe3OjeR?=				MVTJR\|UxRTBwNEO4JO69VQ>?	NWS2WmpKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OFIxQTVpPkKzPVQzODl3PD;hQi=>
PC-3	NHviepFCeG:ydH;zbZMhSXO\|YYm=				MkLqTWM2OD1zLke1OUDPxE1?	NXzIPIlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OFIxQTVpPkKzPVQzODl3PD;hQi=>
DU145	NIXn[HlCeG:ydH;zbZMhSXO\|YYm=				NEHDZXNKSzVyPUOuOVE4KM7:TR?=	M17EVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUSyNFk2Lz5{M{m0NlA6PTxxYU6=
RC165N	NXi4N2puSXCxcITvd4l{KEG\|c3H5				NX7XOId{UUN3ME2yMlA5OyEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl2MkC5OUc,OjN7NEKwPVU9N2F-
ARPE19	NUjNcmNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYPEUXNQ	NHzRN2lKSzVyPUK0MlM5KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MUmyNUc,OjN3M{G5NlE9N2F-
HEK293	M1TEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmTJSG1UVw>?	MVPJR\|UxRThwNkeg{txO	NYnhfW9CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|E6OjFpPkKzOVMyQTJzPD;hQi=>
KCNR	MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4X6OWROW09?	NUjScmVpUUN3ME2wMlQ3KM7:TR?=	MnLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{G5NlEoRjJ\|NUOxPVIyRC:jPh?=
SY5Y	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3HifWROW09?	NYDOTJlEUUN3ME2wMlM3KM7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MUmyNUc,OjN3M{G5NlE9N2F-
BE2	Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkWySG1UVw>?	M2rXOWlEPTB;MD63NUDPxE1?	MorRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{G5NlEoRjJ\|NUOxPVIyRC:jPh?=
AS	M2X1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYrEUXNQ	MYfJR\|UxRTFwNUOg{txO	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MUmyNUc,OjN3M{G5NlE9N2F-
NGP	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUHEUXNQ	MV3JR\|UxRTBwNU[g{txO	Mk\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{G5NlEoRjJ\|NUOxPVIyRC:jPh?=
IMR32	NHLaOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXjMPGZrTE2VTx?=	NFLySI1KSzVyPUCuOlYh\|ryP	NXOzepdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|E6OjFpPkKzOVMyQTJzPD;hQi=>
LAN5	NV\TWFZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2PZXmROW09?	MXzJR\|UxRTFwMESg{txO	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MUmyNUc,OjN3M{G5NlE9N2F-
RH18	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWfnfGtjTE2VTx?=	MXLJR\|UxRTFwNEKg{txO	NHfsWVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNVkzOSd-MkO1N\|E6OjF:L3G+
RH30	NV\OPYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX3EUXNQ	NFTMNHZKSzVyPUGuNlUh\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MUmyNUc,OjN3M{G5NlE9N2F-
RH17	NWSzdHNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVPEUXNQ	NUPQdog2UUN3ME2yMlUyKM7:TR?=	M1\SUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUOxPVIyLz5{M{WzNVkzOTxxYU6=
RH28	M3Xvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUDJXGU{TE2VTx?=	NYL4UHRuUUN3ME20MlI5KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MUmyNUc,OjN3M{G5NlE9N2F-
RH36	M4\SSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGnOd5BFVVOR	MkfUTWM2OD13LkO3JO69VQ>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MUmyNUc,OjN3M{G5NlE9N2F-
RH41	M2rYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{jJVGROW09?	MWjJR\|UxRTBwNEig{txO	NHz5T4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNVkzOSd-MkO1N\|E6OjF:L3G+
RD	MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXzEUXNQ	NHKydotKSzVyPUSuN\|Ih\|ryP	NV;tcFY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|E6OjFpPkKzOVMyQTJzPD;hQi=>
TC32	NWH1fopuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NILRblRFVVOR	NHj1OppKSzVyPUOuPFUh\|ryP	NViwTopmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|E6OjFpPkKzOVMyQTJzPD;hQi=>
TC71	NE\DbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIHCNGdFVVOR	M2LmXGlEPTB;ND6zN{DPxE1?	NHXnV3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNVkzOSd-MkO1N\|E6OjF:L3G+
KCNR	M{WzWmFxd3C2b4Ppd{BCe3OjeR?=	NH7UXFIxNjVxMT6wM\|IvPSEQvF2=	NIrOUI4zPCCq	MnfJSG1UVw>?	MX3pcoR2[2W\|IHHuJIlv[3KnYYPlJIlvKGOjc4Dhd4UhOy95IHHjeIl3cXS7	NXzLeZZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|E6OjFpPkKzOVMyQTJzPD;hQi=>
SY5Y	MVjBdI9xfG:\|aYOgRZN{[Xl?	M1rvZ\|AvPS9zLkCvNk42KM7:TR?=	NE\3Z5IzPCCq	M{mzbWROW09?	Ml3LbY5lfWOnczDhckBqdmO{ZXHz[UBqdiClYYPwZZNmKDNxNzDhZ5Rqfmm2eR?=	NHvJVlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNVkzOSd-MkO1N\|E6OjF:L3G+
Rh18	M1jXXWFxd3C2b4Ppd{BCe3OjeR?=	M3PuOFAvPS9zLkCvNk42KM7:TR?=	M3n0NVI1KGh?	NUDZRoNrTE2VTx?=	Mkf3bY5lfWOnczDhckBqdmO{ZXHz[UBqdiClYYPwZZNmKDNxNzDhZ5Rqfmm2eR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MUmyNUc,OjN3M{G5NlE9N2F-
TC32	Mk\3RZBweHSxc3nzJGF{e2G7	MlLENE42NzFwMD:yMlUh\|ryP	M1LvVVI1KGh?	MlLLSG1UVw>?	M4nnWIlv\HWlZYOgZY4hcW6lcnXhd4UhcW5iY3HzdIF{\SB\|L{egZYN1cX[rdIm=	NGPUW4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNVkzOSd-MkO1N\|E6OjF:L3G+
KCNR	MWLGeY5kfGmxbjDBd5NigQ>?	NGj3ZYYxNjVxMT6wM\|IvPS93IN88US=>	Mke4NlQhcA>?	NWmxe5ZuTE2VTx?=	NUPxOoV1cW6qaXLpeJMh[m:2aDDlcoRw\2Wwb4XzJINwdnO2aYT1eIl3\SCjbnSgTWwuPi2rbnT1Z4VlKFOWQWSzJIFkfGm4YYTpc44>	Mk\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{G5NlEoRjJ\|NUOxPVIyRC:jPh?=
SY5Y	NGTCcIZHfW6ldHnvckBCe3OjeR?=	NH3vUG0xNjVxMT6wM\|IvPS93IN88US=>	Mn;0NlQhcA>?	MmHnSG1UVw>?	MmfzbY5pcWKrdIOgZo91cCCnbnTv[4Vvd3W\|IHPvcpN1cXS3dHn2[UBidmRiSVytOk1qdmS3Y3XkJHNVSVR\|IHHjeIl3[XSrb36=	NIj3NZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNVkzOSd-MkO1N\|E6OjF:L3G+
Rh18	MXXGeY5kfGmxbjDBd5NigQ>?	M2LBO\|AvPS9zLkCvNk42NzVizszN	M3zUW\|I1KGh?	M2HB[GROW09?	M1HnW4lvcGmkaYTzJIJwfGhiZX7kc4dmdm:3czDjc45{fGm2dYTpeoUh[W6mIFnMMVYucW6mdXPl[EBUXEGWMzDhZ5RqfmG2aX;u	NFTKPFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNVkzOSd-MkO1N\|E6OjF:L3G+
TC32	NHOzOFNHfW6ldHnvckBCe3OjeR?=	NGWwUGgxNjVxMT6wM\|IvPS93IN88US=>	NFS1UYgzPCCq	MUDEUXNQ	NV65eo11cW6qaXLpeJMh[m:2aDDlcoRw\2Wwb4XzJINwdnO2aYT1eIl3\SCjbnSgTWwuPi2rbnT1Z4VlKFOWQWSzJIFkfGm4YYTpc44>	NFvBWGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNVkzOSd-MkO1N\|E6OjF:L3G+
TPC-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYC1TW5OOSEEtV2=	MYCwMVQh\A>?	MVXEUXNQ	MnrqbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[W[2ZYKgNkBlKHS{ZXH0cYVvfA>?	NYLTXJpjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOVY1QTlpPkKzNFU3PDl7PD;hQi=>
MZ-CRC1	M2fiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHPSHhPOSEEtV2=	MmHmNE02KGR?	MYnEUXNQ	Mn7EbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[W[2ZYKgNUBlKHS{ZXH0cYVvfA>?	M1zsdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEW2OFk6Lz5{M{C1OlQ6QTxxYU6=
TT	NYDKdGRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;TNUDDvU1?	NHu4UYsxNTRiZB?=	MXzEUXNQ	MYnpcohq[mm2czDj[YxtKGe{b4f0bEBi\nSncjCxJIQhfHKnYYTt[Y51	Mnz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNU[0PVkoRjJ\|MEW2OFk6RC:jPh?=
TPC-1	M4DtZWZ2dmO2aX;uJGF{e2G7	NYTKfFhoOSEEtV2=	NGnGe2s4OiCq	NHLhZ\|RFVVOR	NIr3fHJqdmS3Y3XzJGcyKGKub3PrZYdm	MlfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNU[0PVkoRjJ\|MEW2OFk6RC:jPh?=
MZ-CRC1	NVvZTnd4TnWwY4Tpc44hSXO\|YYm=	NFzXZooyKML3TR?=	NXn3SWtnPzJiaB?=	NH3XXHJFVVOR	NH;wTINqdmS3Y3XzJGcyKGKub3PrZYdm	M2PLW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEW2OFk6Lz5{M{C1OlQ6QTxxYU6=
TT	MVjGeY5kfGmxbjDBd5NigQ>?	MUGxJOK2VQ>?	MV[3NkBp	M3rMfmROW09?	MXnpcoR2[2W\|IFexJIJtd2OtYXfl	MoTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNU[0PVkoRjJ\|MEW2OFk6RC:jPh?=
MZ-CRC1	M1HvXWFxd3C2b4Ppd{BCe3OjeR?=	MkfzNUDDvU1?	MY[0PEBp	NHvOOVBFVVOR	MmjmbY5lfWOnczDhdI9xfG:\|aYO=	M3zOTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEW2OFk6Lz5{M{C1OlQ6QTxxYU6=
TT	MmnFRZBweHSxc3nzJGF{e2G7	Mm\WNUDDvU1?	M3zSfVQ5KGh?	M33lXGROW09?	MmjPbY5lfWOnczDhdI9xfG:\|aYO=	NIrSR3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1OlQ6QSd-MkOwOVY1QTl:L3G+
HD-LM2	NFXk[\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH\CR3M4OuLCiXi=	MUjEUXNQ	MUTJR\|UxRTdwOES0JO69VQ>?	NILBfpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyPVA6PCd-MkK4NlkxQTR:L3G+
L-428	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFHXV\|Y4OuLCiXi=	M{XDcWROW09?	MVvJR\|UxRTdwOUS3JO69VQ>?	NE\yNJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyPVA6PCd-MkK4NlkxQTR:L3G+
KM-H2	NYSwTIFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3;URlcz6oDLaB?=	M1fkOGROW09?	M3\afmlEPTB;MT6zNFgh\|ryP	NGfXXm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyPVA6PCd-MkK4NlkxQTR:L3G+
L-540	MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH;xTGc4OuLCiXi=	NVfUTnVOTE2VTx?=	MkXYTWM2OD16LkKxOkDPxE1?	NFGxZVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyPVA6PCd-MkK4NlkxQTR:L3G+
HD-LM2	MYnGeY5kfGmxbjDBd5NigQ>?	M2HCU\|AvOS9yLkWvNU82KM7:TR?=	Mkf5O\|LjiImq	MXPEUXNQ	MYHpcohq[mm2czDTWGFVOyxiU2TBWFUh[W6mIGPURXQ3KHCqb4PwbI9zgWyjdHnvci=>	MmnSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MkmwPVQoRjJ{OEK5NFk1RC:jPh?=
L-428	MVjGeY5kfGmxbjDBd5NigQ>?	Mk\vNE4yNzBwNT:xM\|Uh\|ryP	NGXpUYM4OuLCiXi=	NInlTIlFVVOR	NXvoZWY6cW6qaXLpeJMhW1SDVEOsJHNVSVR3IHHu[EBUXEGWNjDwbI9{eGixconsZZRqd25?	NIPxT4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyPVA6PCd-MkK4NlkxQTR:L3G+
KM-H2	MXHGeY5kfGmxbjDBd5NigQ>?	MmrLNE4yNzBwNT:xM\|Uh\|ryP	NVPwR2dwPzMkgJno	NX\QRYFrTE2VTx?=	NVXmeWpncW6qaXLpeJMhW1SDVEOsJHNVSVR3IHHu[EBUXEGWNjDwbI9{eGixconsZZRqd25?	NWfWXWlPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlkxQTRpPkKyPFI6ODl2PD;hQi=>
L-540	NVLhPXdQTnWwY4Tpc44hSXO\|YYm=	MlnVNE4yNzBwNT:xM\|Uh\|ryP	M1vtXVcz6oDLaB?=	MXnEUXNQ	NH3hOXdqdmirYnn0d{BUXEGWMzygV3RCXDViYX7kJHNVSVR4IIDoc5NxcG:{eXzheIlwdg>?	MlHmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MkmwPVQoRjJ{OEK5NFk1RC:jPh?=
HD-LM2	MUXBdI9xfG:\|aYOgRZN{[Xl?	MXexM\|Uh\|ryP	M4XEbVcz6oDLaB?=	M{jKemROW09?	MWDpcoR2[2W\|IHHwc5B1d3Orcx?=	M2rhelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK5NFk1Lz5{MkiyPVA6PDxxYU6=
L-428	MmmzRZBweHSxc3nzJGF{e2G7	M4\NeVEwPSEQvF2=	MUC3NwKBkWh?	NVrzWHl7TE2VTx?=	MknkbY5lfWOnczDhdI9xfG:\|aYO=	NHLQdW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyPVA6PCd-MkK4NlkxQTR:L3G+
KM-H2	MX\BdI9xfG:\|aYOgRZN{[Xl?	M{fHT\|EwPSEQvF2=	NX3UV4ZTPzMkgJno	MnjISG1UVw>?	NWLyUHdRcW6mdXPld{BieG:ydH;zbZM>	NWGz[ng1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlkxQTRpPkKyPFI6ODl2PD;hQi=>
L-540	M{PBRmFxd3C2b4Ppd{BCe3OjeR?=	NUPMenhIOS93IN88US=>	M1G4VFcz6oDLaB?=	M1zy[WROW09?	NWrF[pljcW6mdXPld{BieG:ydH;zbZM>	MlzmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MkmwPVQoRjJ{OEK5NFk1RC:jPh?=
U251-MG	M1LTUmZ2dmO2aX;uJGF{e2G7	MXSxJOK2VQ>?	MVmwMVE3KGh?		NF\NZnNqdmirYnn0d{Bkd26\|dHn0eZRqfmViU2TBWE0{KGGwZDDKRWszKGGldHn2ZZRqd25?	M4K5dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEK3OlkyLz5{MkCyO\|Y6OTxxYU6=
U87-MG	MVHGeY5kfGmxbjDBd5NigQ>?	NGm4eJoyKML3TR?=	NEnhdpYxNTF4IHi=		NGXjW2tqdmirYnn0d{Bkd26\|dHn0eZRqfmViU2TBWE0{KGGwZDDKRWszKGGldHn2ZZRqd25?	NInPfVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCyO\|Y6OSd-MkKwNlc3QTF:L3G+
4C8	MWTGeY5kfGmxbjDBd5NigQ>?	NH7Pco4yKML3TR?=	M17nR\|AuOTZiaB?=		M2C5OIlvcGmkaYTzJINwdnO2aYT1eIl3\SCVVFHUMVMh[W6mIFrBT\|Ih[WO2aY\heIlwdg>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB{N{[5NUc,OjJyMke2PVE9N2F-
U251-MG	NUHBRldXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrwNU8yOCEEtV2=	MVSyOE81QC95MjDo		MkOybY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIF1KGFiY3;uZ4VvfHKjdHnvckBw\iBzMDFCuW0>	NYTtc4U{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNlc3QTFpPkKyNFI4PjlzPD;hQi=>
U87-MG	NV7pfnY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;NO4QyNzFyINM1US=>	MoGyNlQwPDhxN{KgbC=>		NEm0T2pqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[XRiYTDjc45k\W62cnH0bY9vKG:oIEGwJOK2VQ>?	NXHQUJlsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNlc3QTFpPkKyNFI4PjlzPD;hQi=>
4C8	M3TLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDKNU8yOCEEtV2=	Ml;KNlQwPDhxN{KgbC=>		M2fCOYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBifCCjIHPvcoNmdnS{YYTpc44hd2ZiMUCgxtVO	NEi5VnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCyO\|Y6OSd-MkKwNlc3QTF:L3G+
U266	M2qwNmFxd3C2b4Ppd{BCe3OjeR?=	NVPGXYVrOC53LUKg{txO	MYC0PE84OiCq		MUHpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NGXsNlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG2OFUyPyd-MkGxOlQ2OTd:L3G+
Kms.11	Mn64RZBweHSxc3nzJGF{e2G7	MmHkNE42NTJizszN	MUm0PE84OiCq		M4LUe4lv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm=	M1T0bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMU[0OVE4Lz5{MUG2OFUyPzxxYU6=
8226	NXjGWWh5SXCxcITvd4l{KEG\|c3H5	NIewWIoxNjVvMjFOwG0>	Moe1OFgwPzJiaB?=		Mmq0bY5lfWOnczDhdI9xfG:\|aYOg[I9{\SCmZYDlcoRmdnSueR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF4NEWxO{c,OjFzNkS1NVc9N2F-
SET2	M4rlfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGjIPYQ1QCCqcoO=		M2\zTWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNGXDJiY3XscJMh\XiycnXzd4lv\yCMYXuyJHY3OTeIIH31eIFvfCCjZoTldkA1QCCqcoOgZpkhVVSVIHHzd4F6NCCJSUWwJF0hOC5yMU[g{txONg>?	NWi1ZWQ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxN\|gzPDZpPkKxNVM5OjR4PD;hQi=>
SET2	MlXDSpVv[3Srb36gZZN{[Xl?		NVvpfVc{OSCqch?=		NY\XVXcxUW6qaXLpeIlwdiCxZjDTeIF1OyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hW0WWMjDj[YxteyCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfHSrbnesJGlEPTBiPTCwMlAzOyEQvF2u	NG\DRWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGzPFI1Pid-MkGxN\|gzPDZ:L3G+
SET2	MoexSpVv[3Srb36gZZN{[Xl?		NF\ne\|QyKGi{		NFjjUY5KdmirYnn0bY9vKG:oIGP0ZZQ2KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBUTVR{IHPlcIx{KGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91fGmwZzygTWM2OCB;IECuNFI2KM7:TT6=	NX\yVYt7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxN\|gzPDZpPkKxNVM5OjR4PD;hQi=>
HEL	Mln5SpVv[3Srb36gZZN{[Xl?		M4\qflEhcHJ?		NXLZZZUyUW6qaXLpeIlwdiCxZjDTeIF1PSCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUEWOIHPlcIx{KGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91fGmwZzygTWM2OCB;IECuNFQyKM7:TT6=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF\|OEK0Okc,OjFzM{iyOFY9N2F-
Ba/F3	M4q0NmZ2dmO2aX;uJIF{e2G7				MnLVTY5pcWKrdHnvckBw\iCVdHH0OUBxcG:\|cHjvdplt[XSrb36gbY4hdW:3c3WgRoEwTjNiY3XscJMh\XiycnXzd4lv\yCWRVytToFsOixiSVO1NEA:KDBwMES2JO69VS5?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF\|OEK0Okc,OjFzM{iyOFY9N2F-
UKE1	Ml\lS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3TSOFQ5KGi{cx?=		Ml7uS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWWtGOSClZXzsd{BmgHC{ZYPzbY5oKEqja{KgWlYyP0ZibYX0ZY51KGGodHXyJFQ5KGi{czDifUBOXFNiYYPzZZktKEeLNUCgQUAxNjB3NDFOwG0v	M3njR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUO4NlQ3Lz5{MUGzPFI1PjxxYU6=
BA/F3	M3;Md2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1j2SlQ5KGi{cx?=		NGP3NZZIem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIGTlcE1LSUt{IHvpcoF{\SCjZoTldkA1QCCqcoOgZpkhVVSVIHHzd4F6NCCJSUWwJF0hOC5yNjFOwG0v	M3nXWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUO4NlQ3Lz5{MUGzPFI1PjxxYU6=
HEL	MlzCSpVv[3Srb36gZZN{[Xl?		M1\V[lEhcHJ?		Mn3XTY5pcWKrdHnvckBw\iCVdHH0N{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gTGVNKGOnbHzzJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0eIlv\yxiSVO1NEA:KDBwMEig{txONg>?	NHi2d2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGzPFI1Pid-MkGxN\|gzPDZ:L3G+
HEL	NEn1Z2JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVjzfGRMPDhiaILz		Mlv2S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGVNKGOnbHzzJIV5eHKnc4PpcochUmGtMjDWOlE4TiCvdYThcpQh[W[2ZYKgOFghcHK\|IHL5JG1VWyCjc4PhfUwhT0l3MDC9JFAvOzlizszNMi=>	NELDcnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGzPFI1Pid-MkGxN\|gzPDZ:L3G+
BA/F3	NI\xXoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVi0PEBpenN?		NFOzem5Iem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIGTlcE1LSUtzIHvpcoF{\SCjZoTldkA1QCCqcoOgZpkhVVSVIHHzd4F6NCCJSUWwJF0hOC55IN88UU4>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF\|OEK0Okc,OjFzM{iyOFY9N2F-
BA/F3	NGflXZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MV60PEBpenN?		MlK3S5Jwf3SqIHnubIljcXSrb36gc4YhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCWZXytWJlsOiCtaX7hd4Uh[W[2ZYKgOFghcHK\|IHL5JG1VWyCjc4PhfUwhT0l3MDC9JFIh\|ryPLh?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF\|OEK0Okc,OjFzM{iyOFY9N2F-
BA/F3	MnvSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{PiPFQ5KGi{cx?=		M1L3OWdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiVHXsMWpCUzNia3nuZZNmKGGodHXyJFQ5KGi{czDifUBOXFNiYYPzZZktKEeLNUCgQUAzNjFizszNMi=>	NIHIdZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGzPFI1Pid-MkGxN\|gzPDZ:L3G+
UKE1	NFjmU4NHfW6ldHnvckBie3OjeR?=		NWPaTlljOSCqch?=		NHj0UHBKdmirYnn0bY9vKG:oIGP0ZZQ2KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBWU0VzIHPlcIx{KGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91fGmwZx?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF\|OEK0Okc,OjFzM{iyOFY9N2F-
SW620	MV3D[YxtKGO7Y3zlJIF{e2G7	M1PBclMvOyC3TR?=	Mn\rNlQhcHK\|		NGn5dotE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBUXzZ{MDDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG\|ZTDheEA{NjNidV2gZYZ1\XJiMkSgbJJ{KGK7IH\sc5ch[3m2b33leJJ6	Ml;OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzM{iyOFYoRjJzMUO4NlQ3RC:jPh?=
HEL	NXzxcmFHTnWwY4Tpc44h[XO\|YYm=	M1jmblAvOyC3TR?=	NH7V[I42KG2rboO=		M3;EO2lvcGmkaYTpc44hd2ZiU4TheFUheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGhGVCClZXzsd{BifCByLkOgeW0h[W[2ZYKgOUBucW6\|IHL5JHdme3Sncn6gZoxwfHSrbne=	M4q1elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUO4NlQ3Lz5{MUGzPFI1PjxxYU6=
HEL	MXnGeY5kfGmxbjDhd5NigQ>?	M4TMclAvOyC3TR?=	M{jJPFMxKHSxIE[wJI1qdnN?		MWrJcohq[mm2aX;uJI9nKFO2YYS1JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDISWwh[2WubIOgZZQhOC5\|IIXNJIFnfGW{IEOwJJRwKDZyIH3pcpMh[nliV3XzeIVzdiCkbH;0eIlv\w>?	MnXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzM{iyOFYoRjJzMUO4NlQ3RC:jPh?=
BA/F3	MlG5RY51cXS3bX;yJIF{e2G7	NXXXT\|R1OzBibXevb4c>	MWmxNkBpenN?		M4\T[WFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochXGWuLVrBT\|IhgGWwb3fyZYZ1\WRiaX6gUmNzKG2xdYPlJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVdHH0OUBt\X[nbDDpckB{eGynZX6gZZQhOzBibXevb4ctKHCxIHHmeIVzKDF{IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5o	MmraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzM{iyOFYoRjJzMUO4NlQ3RC:jPh?=
HEL	M3iwUWZ2dmO2aX;uJIF{e2G7	MUCwMlMhfU1?	MX21JI1qdnN?		MlHhTY5pcWKrdHnvckBw\iCVdHH0N{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gTGVNKGOnbHzzJIF1KDBwMzD1UUBi\nSncjC1JI1qdnNiYomgW4V{fGW{bjDicI91fGmwZx?=	NInDUHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGzPFI1Pid-MkGxN\|gzPDZ:L3G+
HEL	NUXLZlRUTnWwY4Tpc44h[XO\|YYm=	NFvB[XMxNjNidV2=	M4LlbFMxKHSxIE[wJI1qdnN?		NGXscWFKdmirYnn0bY9vKG:oIGP0ZZQ{KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBJTUxiY3XscJMh[XRiMD6zJJVOKGGodHXyJFMxKHSxIE[wJI1qdnNiYomgW4V{fGW{bjDicI91fGmwZx?=	NHPsdGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGzPFI1Pid-MkGxN\|gzPDZ:L3G+
Hs578T	NX7KeZp3TnWwY4Tpc44h[XO\|YYm=	MV6xJJVO	NU\O[2JDOjRiaILz		M1\VS2lvcGmkaYTpc44hd2ZiU2TBWFNENW2nZHnheIVlKHS{YX7zZ5JqeHSrb36gbY4hcHWvYX6gTJM2PziWIHPlcIx{KGG2IEGgeW0h[W[2ZYKgNlQhcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>?	NFLZbmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm3PFEyOid-MkS5O\|gyOTJ:L3G+
NCI-H1975	Ml;DSpVv[3Srb36gZZN{[Xl?	MnzvNE4xODNidH:gN{B2VQ>?	MUSyJIhzew>?		MWXJcohq[mm2aX;uJI9nKEqDS{GgbY4hcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCVVFHUN{BxcG:\|cHjvdplt[XSrb36gZZQhOC5yMEOgeI8hOyC3TTDh[pRmeiB{IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	M4rieFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkG0OFA5Lz5{Nk[xOFQxQDxxYU6=
HEL 92.1.7	NGLkRodHfW6ldHnvckBie3OjeR?=		NVTK[m94OiCqcoO=		NVjQbGdEUW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKEiHTDC5Nk4yNjdiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHNVSVR3IIDoc5NxcG:{eXzheIlwdiCjZoTldkAzKGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NGDK[Yc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[xOFQxQCd-Mk[2NVQ1ODh:L3G+
DAOY	NXjsVJl3eUiWUzDhd5NigQ>?				M3O5VZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	NHSyTYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	M{LyOpFJXFNiYYPzZZk>				M3mwS5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NGrK[4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	NIK1coZyUFSVIHHzd4F6				M2f3UZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	NF;BT\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NYjDRXJ7eUiWUzDhd5NigQ>?				Mm\OdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	NHntPGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	NWO1PWFseUiWUzDhd5NigQ>?				MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	NIXhOpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	M2fqWJFJXFNiYYPzZZk>				MkXwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	NVj6bVBneUiWUzDhd5NigQ>?				M13GNJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	NGLvXXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	M1\tUpFJXFNiYYPzZZk>				NH7FcmVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	NEnu[oE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MmTYdWhVWyCjc4PhfS=>				NEHEfmZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	M1fwUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	MVrxTHRUKGG\|c3H5				MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	MoHkdWhVWyCjc4PhfS=>				NEfyPYRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	NF7KWlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	MWTxTHRUKGG\|c3H5				MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	M1jYS5FJXFNiYYPzZZk>				MkC3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	NF7XfFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	Mlv4dWhVWyCjc4PhfS=>				NWLGU\|R{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-STAT3 / STAT3 / p-JAK2 / JAK2 ; PubMed: 22027691 Mol Cancer Ther Cells were treated with AZD1480 for the indicated times, lysed and immunoblotted with the indicated antibodies. p-STAT1 / STAT1 / p-STAT5 / STAT5 / p-STAT6 / STAT6 ; PubMed: 22829094 Blood Cancer J Western blot assay of the four HL cell lines treated with increasing doses of AZD1480 (0.1–5 μM) for 72 h. p-ERK / ERK / p-p38 / p38 / SOCS3 / p-SHP2 / SHP2 ; PubMed: 22829094 Blood Cancer J Representative western blot assay showing increased levels of ERK, p38 and SHP-2 phosphorylation in HD-LM2 and L-428, after treatment for 72 h with increasing doses of AZD1480 (0.1-5 μM). In contrast, L-540 showed a dose-dependent inhibition of ERK and p38 activation without increased SHP-2 phosphorylation. SOCS-3 levels decreased in all the cell lines.	22027691 22829094
Immunofluorescence	pSTAT5; PubMed: 30140255 Front Endocrinol (Lausanne) HepG2 cells were incubated in the presence of Pro-Gly (0.5 mM) and/or AZD1480 (1 μM) for 6 h and phospho-STAT5 translocation to nuclei was detected by ICC. Scale bar, 10 μm. The IP and ICC experiments were conducted independently for 3 times, with 3 replicates each time.	30140255
Growth inhibition assay	Cell proliferation ; PubMed: 22027691 Mol Cancer Ther Cells were treated with AZD1480 for the indicated times, and the WST-1 cell proliferation assay performed. The 48 and 72 h time points were statistically significant. Data represent mean ± SD, replicates of three (**, p<0.001; ANOVA). Cell viability; PubMed: 25855603 Blood IL-3-independent Ba/F3 cells were treated with increasing concentrations of the JAK inhibitor AZD1480 showing submicromolar inhibition of proliferation.	22027691 25855603

体内研究

AZD1480作用于人类实体瘤模型和多发性骨髓瘤模型，抑制 STAT3磷酸化。^[1]在体内, AZD1480抑制皮下移植瘤的生长，且通过抑制STAT3活性提高携带颅内恶性胶质瘤(GBM)的鼠寿命，说明AZD1480抑制JAK/STAT3通路的药理学可以用于研究治疗携带颅内恶性胶质瘤的患者。^[3]AZD1480抑制骨髓细胞的肺浸润和肺转移瘤。AZD1480作用于人类移植瘤模型降低血管生成和代谢。^[4]AZD1480抑制含有STAT活性的人类实体瘤的生长。^[5]

激酶实验：^[5]	- 合并激酶实验: 在有buffer(包括50 mM HEPES pH 为7.3, 1 mM DTT, 0.01% Tween-20, 50 µg/ml BSA,及10 mM MgCl₂)的条件下，使用重组Jak1, Jak2, 或Jak3进行AZD1480抑制效果研究。在昆虫细胞中，Jak3酶表达为氮端GST融合蛋白，且通过谷胱甘肽亲和及尺寸排除色谱来纯化Jak3酶。加入AZD1480 (10点剂量反应, 重复三次, 8.3 µM 到0.3 nM )，使用1.5 µM 肽底物(Jak1:FITC-C6-KKHTDDGYMPMSPGVA-NH2, Jak2和Jak3: FAM-SRCtide)，及各自ATP K_m (Jak1: 55 µM, Jak2: 15 µM, Jak3: 3 µM)，ATP浓度为5 mM，进行酶实验。分离磷酸化和未磷酸化的肽段，使用Caliper LC3000系统计算抑制百分率。
细胞实验：^[4]	- 合并 Cell lines: Renca或786-O细胞，鼠内皮细胞和脾CD11b+/c−骨髓细胞, HUVECs Concentrations: 1 μM Incubation Time: 48或24小时 Method: Renca或786-O细胞悬浮在含5%FBS的DMEM培养基中,按每孔5×10³个细胞接种在96孔板上，使细胞粘附，实验组用AZD1480，对照组用DMSO，处理48小时。通过MTS实验测定细胞活力。使用Mikrotek Laborsysteme在490nm处测定吸光值。鼠内皮细胞和脾CD11b+/c− 骨髓细胞从携带肿瘤的鼠中富集得到，培养在含5% FBS的RPMI-1640培养基上。HUVECs 培养在胶原1包被的含完全培养基的板上。用DMSO和不同剂量AZD1480处理所有细胞，持续24小时。手动计算细胞数而测定细胞活力。所有实验重复三次。 (Only for Reference)
动物实验：^[4]	- 合并 Animal Models: 雌性BALB/c和无胸腺鼠(NCR− nu/nu) (7-8周大) Dosages: 每天一次，剂量为50 mg/kg；或者每天两次，剂量为30 mg/kg Administration: 口服饲喂 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	69 mg/mL warmed (197.83 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 30% PEG400+0.5% Tween80+5% propylene glycol	5 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download AZD1480 SDF

分子量	348.77
化学式	C₁₄H₁₄ClFN₈
CAS号	935666-88-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01219543	Terminated	Drug: AZD1480 Daily\|Drug: AZD1480 BID	Solid Tumour\|Advanced Solid Malignancies\|Child-Pugh A to B7 Advanced Hepatocellular Carcinoma\|EGFR and/or ROS Mutant NSCLC\|Lung Metastasis Carcinoma\|Gastric Cancer	AstraZeneca	November 2010	Phase 1
NCT01112397	Terminated	Drug: AZD1480	Solid Malignancies	AstraZeneca	April 2010	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

JAK Signaling Pathway Map

JAK Inhibitors with Unique Features

泛JAK抑制剂

Ruxolitinib (INCB018424) : Pan JAK1/2 inhibitor, IC50=3.3 nM/2.8 nM.
FDA批准的JAK抑制剂

Tofacitinib (CP-690550,Tasocitinib) : Approved by FDA for rheumatoid arthritis (RA).
最新的JAK抑制剂

XL019 ^New : Potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2.
经典的JAK抑制剂

AG-490 (Tyrphostin B42) : Potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM; also potent to Aurora A/B, Abl(T315I). Phase 1/2.

研究领域

产品类型

定制您的化合物库

AZD1480

客户使用Selleck生产的AZD1480发表文献87篇：

产品安全说明书

JAK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download AZD1480 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

JAK Signaling Pathway Map

JAK Inhibitors with Unique Features

相关JAK产品